Biosimilar arthritis drug shows promise in small study
NCT ID NCT03885037
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a biosimilar version of the drug infliximab (made by Pfizer) in 77 people with rheumatoid arthritis. The goal was to see how safe and effective it is in real-world use. Participants received the drug by IV infusion, and researchers tracked side effects and disease activity over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
infliximab biosimilar (Pfizer)
What this could lead to
If successful, this could provide a more affordable treatment option for rheumatoid arthritis.
What could go wrong
This is a small, completed study without a control group, so results may not be generalizable. Biosimilars may have subtle differences in effectiveness or side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Local Country Office
Tokyo, Japan